A Phase 4 interventional study of Buccal midazolam and Intramuscular midazolam in Seizures, sponsored by Hamad Medical Corporation. Completed at 1 site in Qatar. Open to participants aged 6 Months to 14 Years. Per ClinicalTrials.gov, last updated 2019-07-24.
Sponsored by Hamad Medical Corporation · Phase 4, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
The goal of this study is to prove that intramuscular midazolam is more effective than buccal midazolam in cessation of seizure activity with comparable side effects.
Both buccal and intramuscular midazolam have been used to control seizures with variable succuss rates and side effects.
In this study the investigators are going to assign patient randomly to receive either buccal or intramuscular midazolam. Then will compare both efficacy and side effect in both groups.
766 studies on the registry are indexed under Seizures; 134 are open to participants now.
This study's enrollment of 150 is above the median of 64 across 519 interventional studies indexed under Seizures.
Browse Seizures studies →Hamad Medical Corporation is the lead sponsor of 139 studies on the registry; 27 are open to participants now.
Counted across the registry records on this site, refreshed daily.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Study subject will receive buccal midazolam and intramuscular placebo. The dose of buccal midazolam is 0.3 mg/kg
Drug: Buccal midazolam
Study subject will receive intramuscular midazolam and buccal placebo. The dose of intramuscular midazolam is 0.25 mg/kg.
Drug: Intramuscular midazolam
Study subject will receive Buccal midazolam, Intramuscular placebo.
Study subject will receive Intramuscular midazolam,Buccal placebo
Cessation of seizure activity five minutes after treatment with study medication.
Cessation of abnormal motor activity with regaining of consciousness.
Time frame: five minutes
Major side effects.
Time frame: 2 hours after cessation of seizures.
Duration of seizure.
Time frame: 5 minutes
Recurrence of seizure activity within one hour after treatment with study medication.
Time frame: one hour
Plan to share: No
No publications or documents are linked to this record.
Ran from Sep 2016 to primary completion in Nov 2018, 26 months.
Of 26 phase 4 interventional studies under Seizures, half reached primary completion within 28 months of starting (the median), counting those still running; a quarter within 20 and three quarters within 42. This study's 26 months is close to that.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in Jul 2019. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: Midazolam